These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 17912526)
1. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312 [TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784 [TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. Chang SB; Miron P; Miron A; Iglehart JD J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887 [TBL] [Abstract][Full Text] [Related]
5. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Bundscherer A; Hafner C; Maisch T; Becker B; Landthaler M; Vogt T Oncol Rep; 2008 Feb; 19(2):547-53. PubMed ID: 18202806 [TBL] [Abstract][Full Text] [Related]
7. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Mondesire WH; Jian W; Zhang H; Ensor J; Hung MC; Mills GB; Meric-Bernstam F Clin Cancer Res; 2004 Oct; 10(20):7031-42. PubMed ID: 15501983 [TBL] [Abstract][Full Text] [Related]
8. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917 [TBL] [Abstract][Full Text] [Related]
9. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953 [TBL] [Abstract][Full Text] [Related]
10. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512 [TBL] [Abstract][Full Text] [Related]
11. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. Hsiao JR; Leu SF; Huang BM J Oral Pathol Med; 2009 Feb; 38(2):188-97. PubMed ID: 19200178 [TBL] [Abstract][Full Text] [Related]
12. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872 [TBL] [Abstract][Full Text] [Related]
14. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904 [TBL] [Abstract][Full Text] [Related]
15. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745 [TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Lee JW; Park JK; Lee SH; Kim SY; Cho YB; Kuh HJ Anticancer Drugs; 2006 Apr; 17(4):377-84. PubMed ID: 16549994 [TBL] [Abstract][Full Text] [Related]
17. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200 [TBL] [Abstract][Full Text] [Related]
18. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin. Jaglowski JR; Stack BC Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572 [TBL] [Abstract][Full Text] [Related]
19. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840 [TBL] [Abstract][Full Text] [Related]
20. [Effect of chemotherapy with cisplatin and rapamycin against Hep-2 cells in vitro]. Lei WB; Jia T; Su ZZ; Wen WP; Zhu XL Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1838-41. PubMed ID: 18971185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]